Best Testosterone Booster Supplements For Men: New Report Reveals Which Products Actually Work.
New York, April 30, 2025 (GLOBE NEWSWIRE) --WhatBest, a trusted resource for product research and rankings, has officially announced its list of the top 5 best testosterone boosters for men, showcasing five high-performing supplements identified through more than two years of hands-on testing and ingredient evaluation.
The article is designed to help men find natural testosterone support tailored to their unique needs. The article, now live on WhatBest's website, focuses on five main categories:
Best overall testosterone booster
Best for building muscle
Best for anti-aging
Best for sex drive and workout performance
Best natural testosterone booster
'We created this guide to cut through the noise and help men choose testosterone boosters that align with real goals and real outcomes,' 'Our testing focused on how each formula performed in everyday life not just what it said on the label.'
Read the full testosterone booster rankings on WhatBest.com here.
The WhatBest editorial team examined dozens of popular testosterone supplements and selected the five best-performing options based on their specific strengths. Each was chosen for excelling in one of the following user-focused categories:
Best Overall Testosterone Booster For Men
When evaluating the best overall testosterone booster, our focus was on a formula that offered comprehensive benefits across a variety of wellness categories.
This meant balancing testosterone enhancement with support for energy, strength, muscle development, mood, and mental clarity.
The ideal product would offer a reliable boost in testosterone while helping users feel better throughout the day, both physically and mentally.
Winner: TestoPrime
TestoPrime rose to the top for its all-natural formula, which includes ingredients like D-Aspartic Acid, Ashwagandha, and Panax Ginseng. This combination works synergistically to increase testosterone levels while simultaneously improving overall energy and mental clarity. Additionally, TestoPrime's formula provides notable benefits in reducing stress and supporting muscle strength. In personal use, it delivered consistent results in a safe and effective manner, without the negative side effects commonly associated with some other testosterone supplements.
Best for Building Muscle and Strength
When it comes to muscle and strength, we needed to find a testosterone booster that not only increased testosterone levels but also provided additional support for muscle growth and recovery.
Key ingredients for this category included those known to improve protein synthesis, accelerate recovery times, and enhance workout performance.
Winner: Testo-Max "Testo-Max, designed as a natural alternative to anabolic steroids, was the clear leader in this category. It contains a potent blend of ingredients like D-Aspartic Acid and Fenugreek, which have been shown to enhance testosterone production and muscle-building capabilities. During testing, Testo-Max significantly boosted strength and muscle mass, providing faster recovery and improved performance during intense workouts. Athletes and bodybuilders looking to maximize their gains will find Testo-Max delivers noticeable results within weeks."
Best for Anti-Aging and Vitality
For men experiencing age-related testosterone decline, our top pick needed to do more than just boost testosterone.
We were looking for a formula that improved energy, vitality, mental focus, and overall wellness key factors for fighting the signs of aging.
We also prioritized ingredients with well-researched anti-aging properties that support long-term physical and cognitive health.
Winner: Hunter Test Hunter Test stood out due to its carefully formulated blend of ingredients like D-Aspartic Acid, Vitamin D3, and Ashwagandha, which target the specific needs of aging men. This product helped boost testosterone levels while improving energy, mental clarity, and muscle maintenance. For men in their 30s or 40s looking to combat the effects of aging, Hunter Test not only restores vitality but also supports long-term health. The focus on both mental and physical well-being makes it an excellent choice for anti-aging support.
Best for Sex Drive and Energy
For men looking to enhance their sexual health and overall vitality, the ideal testosterone booster had to deliver noticeable improvements in libido, sexual performance, and energy levels. Ingredients like Zinc, Fenugreek, and Vitamin D were key, as they are known to enhance libido and promote healthy testosterone production.
Winner: TestoFuel TestoFuel's formula is tailored to men looking for a dual-action supplement that enhances both physical and sexual performance. Its powerful blend of D-Aspartic Acid, Oyster Extract (rich in Zinc), and Vitamin D3 supported the body's natural testosterone production while significantly improving libido and workout performance. Users reported feeling more energized during the day, with a notable boost in their sexual drive and stamina. TestoFuel's ability to address both fitness goals and sexual wellness made it a standout in this category.
Best Natural, Single-Ingredient Formula
In this category, we evaluated supplements with a minimalistic approach, using a single, well-researched ingredient to support testosterone levels. These products needed to have scientifically-backed effectiveness while avoiding complex, proprietary blends that may dilute their benefits. We sought out natural amino acids or herbal compounds known for their impact on hormone regulation.
Winner: D-Aspartic Acid (DAA) D-Aspartic Acid (DAA) emerged as the top choice for men seeking a straightforward and natural approach to boosting testosterone. DAA is an amino acid involved in the production of luteinizing hormone, which stimulates testosterone production. Clinical studies have shown DAA can provide a significant boost in testosterone levels, particularly for men with lower baseline levels. While the effects may not be as pronounced as multi-ingredient formulas, DAA offers a natural, effective, and cost-efficient way to support hormonal health without additional fillers or additives.
Research-Based and Experience-Driven
The testosterone booster rankings are the result of a two-year testing initiative led by one of WhatBest's senior contributors, who personally evaluated dozens of products over extended periods.
The testing process included:
Tracking physical performance, mood, energy, and libido
Evaluating clinical support behind key ingredients and dosages
Assessing safety, side effects, and tolerance
Comparing formulation transparency and value for money
Rather than relying on marketing claims, WhatBest based its analysis on how these supplements actually performed in daily life.
'A lot of products sound good on the bottle, but we wanted to know how they feel after 30 days of use,' said the WhatBest team. 'That's where the real difference shows up.'
WhatBest's Approach to Ratings
Each supplement was selected not because it was popular or aggressively marketed, but because it performed best in a specific context. This year's categories were chosen based on common goals shared by men experiencing declining testosterone levels or low energy.
WhatBest evaluated each option on its:
Formulation quality and clinical dosing
User experience and consistency of effects
Specific strengths across categories (e.g., muscle gain, libido)
Transparency and overall safety profile
This format allowed readers to easily identify which supplement may be best suited to their goals not just which scored highest overall.
Trends in Testosterone Supplementation
In addition to ranking top performers, WhatBest's article highlights several emerging trends in the testosterone supplement space:
Natural ingredients over synthetic boosters: More men are looking for herbal or amino acid-based solutions with long-term safety in mind.
Ingredient transparency is now expected: 'Proprietary blends' with vague labeling are losing consumer trust in favor of fully disclosed formulas.
Targeted support is replacing generic claims: Men are shopping based on personal goals such as muscle growth, cognitive performance, or sexual vitality rather than vague promises of "more testosterone."
Lifestyle integration is key: Top-performing supplements worked best when combined with good sleep, strength training, and stress management which is also covered in the blog post.
Where to Read the Full Rankings
The full testosterone booster report, including all five top-performing products, category breakdowns, and real-world testing insights, is now live on the WhatBest website here.
CONTACT: You can contact us at support@whatbest.net or visit our website whatbest.net for more information.Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 hours ago
- Yahoo
Former nurse, 100, 'inundated' with birthday cards
A former midwife has received hundreds of cards from around the world in celebration of her 100th birthday. Bertha Preston spent time working in New Zealand, Australia and Kenya, before settling down in a nursing career at Royal United Hospital (RUH) in Bath, Somerset. With no surviving family or close friends nearby, staff at the Bloomfield Care Centre in Paulton issued a "heartfelt request" to the public to send in their warm wishes. Key worker Jane Rogers described Ms Preston as a "very strong lady", who "chose her career over marriage" and showed an unwavering dedication to her profession. Ms Preston said "her spirit remains strong and her presence continues to inspire those around her". "She's been a huge part of my life," said Ms Rogers, who has cared for Ms Preston since 2009. "All of the residents here are very special to everyone who works here, but she's a darling lady. "Because of her vulnerability and the fact she has no known family, we've all become her family, and that's how we like it." Ms Preston's "quiet strength and compassion" was born out of becoming an orphan at the age of eight, after losing her mother to tuberculosis. Her nursing journey took her around the world, most notably to Africa, where she treated patients for trachoma and helped deliver hundreds of babies. One woman wrote to Ms Preston from Kenya to ask if she had worked at the hospital during her birth in the early 1960s. "I was delighted to read of your enthusiasm for the country, and of your hard work and devotion over many years as a nurse," Sarah wrote. "You are clearly a credit to your profession." Activities assistant Christina Coles said the home had been "inundated" with letters since posting the appeal online, including a card from King Charles III and Queen Camilla. "The amount that's come through the post has been amazing," she said. "We've had such a good response, it's really been overwhelming. "It's lovely that people have made so much effort in the community to come forward for a lady who has worked so hard. "100 years is an amazing achievement for anyone. Bertha has got an incredible story and it's nice to share that with people," she added. Follow BBC Somerset on Facebook and X. Send your story ideas to us on email or via WhatsApp on 0800 313 4630. D-Day veteran's 'unforgettable' 100th birthday World War Two decoder celebrates 100th birthday Vera celebrates 100th birthday with 450 cards Bloomfield Care Centre
Yahoo
2 days ago
- Yahoo
Oregon Sen. Lisa Reynolds mulls conflict of interest declaration after ethics report
Sen. Lisa Reynolds sought clarity from the state's top ethics watchdog over whether a health care bill she authored would pose a substantial conflict of interest. (Rian Dundon/Oregon Capital Chronicle) Oregon's statewide ethics watchdog on Thursday referred a Portland-area lawmaker to the Legislature for clarity over whether a bill she authored that could benefit her medical practice raises a substantial conflict of interest. The Oregon Government Ethics Commission said Sen. Lisa Reynolds' decisions regarding votes and bill introductions were within the purview of the Legislature and its legal counsel, according to a Thursday letter written by Susan Myers, the commission's executive director. Introduced in January, Senate Bill 28 would mandate commercial insurers reimburse independent primary care clinics at rates equal to those of clinics owned by hospital systems. In the letter, Myers said that Reynolds, D-Portland, 'would be met with a conflict of interest' unless she is able to receive a class exception. The rule is traditionally adjudicated by the commission, determining whether an official action by a public official would impact all members of a 'class,' such as business owners or members of a particular industry, equally. But it's up to the Legislature, not the Commission, to decide whether the exception applies because the matter 'relates to the performance of legislative functions,' Myers wrote. Lawmakers are allowed to cast votes and perform legislative tasks under Oregon's 'speech and debate' rules for public officials even when they do declare conflicts of interest. Reynolds told the Capital Chronicle she hasn't decided whether she will seek further advice. She said that she will consult with her staff and tends 'to err on the side of caution.' 'I'll see going forward,' she said. 'It would be interesting to note the votes I've taken. For example, the provider tax which funds Medicaid — do I have to say that's a conflict of interest because my clinic takes Medicaid? I don't think so.' The advice follows a request from the commission in a May 6 letter written by her chief of staff, Christopher McMorran, a day before the Oregon Journalism Project ran a story in which Reynolds said she was open to seeking the ethics' commissions advice and declaring a conflict of interest. McMorran sought information about potential conflicts of interest because of Reynolds' job as a primary care provider at The Children's Clinic, an independent clinic in the Portland region. 'SB 28 would likely result in a financial gain for her clinic, along with all other independent primary care clinics in the state,' he wrote to the commission. 'We are curious if her introducing, sponsoring and supporting this bill qualifies as a conflict of interest or if she would be considered a member of a class and be exempt from conflict of interest laws.' Reynolds said the advice was 'reassuring' and that she believes she would likely qualify for a class exemption. 'I'm a citizen legislator. My day job is that of a pediatrician. In fact, I was in the clinic all last weekend,' she said. 'I still see patients and I actually ran as Dr. Lisa Reynolds. I ran for office leaning into the fact that I am a physician and it informs all that I do in the Legislature.' Her legislation is currently sitting in the Joint Ways and Means Committee. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Yahoo
3 days ago
- Yahoo
PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout
New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New York, May 30, 2025 (GLOBE NEWSWIRE) -- PESG Research is releasing a report today examining PolyPid Ltd.*, an innovative late-stage biopharmaceutical company developing revolutionary localized drug delivery technologies for surgical infection prevention. The below report explores the company's breakthrough PLEX platform technology, its upcoming topline phase 3 data, and potential implications for transforming surgical care practices in the multi-billion dollar surgical site infection prevention market. This report contains sponsored content, please see refer to the disclaimers and disclosures included at the end of this report. Executive Summary The surgical site infection (SSI) prevention landscape stands at a potential inflection point as PolyPid Ltd. prepares to announce topline results from its pivotal SHIELD II Phase 3 trial by the end of Q2 2025. The company's D-PLEX100 represents a paradigm shift in infection prevention, utilizing novel polymer-lipid encapsulation matrix (PLEX) technology to deliver sustained antibiotic release directly at surgical sites for 30 days. With SSIs affecting up to 30% of colorectal surgeries and imposing substantial healthcare costs estimated at $10 billion annually in the US and EU, successful development of D-PLEX100 could address a critical unmet medical need. The FDA's assignment of Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product (QIDP) designations underscores the regulatory recognition of this approach's potential Critical Challenge of Surgical Site Infections Surgical site infections remain one of healthcare's most persistent challenges, representing 20% of all healthcare-associated infections in US hospitals. Despite advances in surgical techniques and prophylactic protocols, SSI rates in high-risk procedures like colorectal surgery can reach 30%, leading to extended hospital stays of 7-11 additional days and mortality risk increases of 2-11 fold. The economic burden is staggering, with direct costs averaging $11,000-26,000 per infection and total annual costs reaching approximately $10 billion in the US alone. Current prevention strategies rely primarily on systemic antibiotic prophylaxis administered intravenously 30-60 minutes before surgery. However, this approach faces fundamental limitations. Surgical incisions disrupt local blood flow, significantly limiting antibiotic penetration to the precise site where infections occur. Moreover, systemic administration exposes patients to higher drug concentrations throughout the body, potentially increasing toxicity risks and contributing to antimicrobial resistance development. PLEX Technology: A Novel Approach to Localized Drug Delivery PolyPid's proprietary PLEX technology represents a sophisticated advancement in controlled drug delivery systems. The platform creates thousands of alternating layers of biocompatible polymers and lipids that physically embed active pharmaceutical ingredients. As these outer layers gradually disintegrate upon exposure to body fluids, they enable precise, predetermined drug release rates spanning several days to months. For D-PLEX100, this technology pairs with doxycycline, a broad-spectrum antibiotic effective against both gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant strains. The formulation achieves local antibiotic concentrations 10-115 times higher than systemic administration while using only a fraction of the total drug amount, potentially minimizing systemic exposure and associated side effects. Clinical Development Progress and Regulatory Recognition The clinical development program for D-PLEX100 has demonstrated encouraging signals across multiple surgical contexts. In Phase 2 abdominal surgery trials, D-PLEX100 plus standard of care achieved a statistically significant 59% reduction in the primary endpoint compared to standard of care alone (p=0.0086). Perhaps more notably, the treatment group experienced zero deaths compared to five in the control arm within 60 days post-surgery. The pivotal SHIELD I Phase 3 trial, while not meeting its primary endpoint in the full intent-to-treat population, revealed compelling efficacy in a pre-specified subgroup analysis. Among patients with large surgical incisions (>20 cm), D-PLEX100 demonstrated a statistically significant 54% reduction in the composite primary endpoint of SSIs, reinterventions, and mortality (p=0.0032). This finding directly informed the design of the ongoing SHIELD II trial, which focuses specifically on this higher-risk patient FDA's regulatory designations reflect recognition of D-PLEX100's potential significance. Breakthrough Therapy designation is reserved for drugs that demonstrate substantial improvement over existing treatments for serious conditions. Fast Track designation facilitates more frequent FDA communications and potentially accelerated review timelines. The QIDP designation provides additional market exclusivity incentives for addressing antimicrobial resistance challenges. SHIELD II: A Potentially Definitive Study The ongoing SHIELD II Phase 3 trial represents a carefully designed study incorporating lessons learned from SHIELD I. Following an independent Data Safety Monitoring Board's review of unblinded efficacy data from the first 430 enrolled patients, the board recommended concluding the study at 800 patients—the lowest sample size reassessment option available. This recommendation, while requiring additional enrollment beyond the initially planned 624 patients, may suggest positive efficacy trends in the analyzed interim data. The study's multinational design spans approximately 60 centers across the United States, Europe, and Israel, enhancing the generalizability of results across different healthcare settings and patient populations. The primary endpoint focuses on a composite of SSI events, reinterventions, and mortality within 30 days post-surgery, as adjudicated by an independent committee. Broader Industry ImplicationsSuccess of D-PLEX100 could catalyze broader adoption of localized drug delivery approaches in surgical settings. The technology's platform nature suggests potential applications beyond infection prevention, including localized chemotherapy delivery through the company's OncoPLEX program, currently in preclinical development for solid tumor treatment. The substantial market opportunity—with approximately 12 million eligible procedures annually in the US and 8 million in Europe—underscores the potential healthcare impact. PolyPid has already secured European commercialization rights through a partnership with Advanz Pharma, valued at up to $115 million plus royalties, while advancing discussions for US market partnerships. Conclusion As the pharmaceutical industry grapples with antimicrobial resistance and healthcare systems seek cost-effective solutions to persistent clinical challenges, D-PLEX100's approaching data readout represents a potentially significant milestone. The convergence of compelling preclinical and early clinical data, regulatory recognition, and substantial unmet medical need positions this development as one to monitor closely in the evolving landscape of surgical infection News Highlight from PolyPid: PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections >> Click here to Subscribe for more updates like this or go to * Legal Disclaimer & Disclosure: Nothing in this report constitutes medical, financial or any form professional or licensedadvice. This report is published by 'PESG Research', a digital promotional content brand who's operators are compensated to provide digestable and favorabel coverage of companies. This report contains and is a form of paid promotional content or advertising for PolyPid Ltd and was produced as part of the fee's they pay PESG's operators, Arx Advisory Ltd. This report has not been reviewed or approved by PolyPId prior to publication and it does not represent an official communication from PolyPid. The operators of PESG Research received or are expected to receive a monthly recurring fee of five thousand united states dollars via wire transfer from PolyPid as part of an ongoing agreement starting May 1, 2025 in return for distribution and promotional coverage services, and receive additional monthly compensation for non promotional unrelated data and advisory services on top of that. Please review the full disclaimers and compensation disclosures here for further details: Readers are advised to refer to the official materials of the company aforementioned. The report should not be treated as objective.
